CORT vs. HRMY, PRGO, SUPN, TARO, PCRX, XNCR, OPK, AVIR, ADCT, and JAZZ
Should you be buying Corcept Therapeutics stock or one of its competitors? The main competitors of Corcept Therapeutics include Harmony Biosciences (HRMY), Perrigo (PRGO), Supernus Pharmaceuticals (SUPN), Taro Pharmaceutical Industries (TARO), Pacira BioSciences (PCRX), Xencor (XNCR), OPKO Health (OPK), Atea Pharmaceuticals (AVIR), ADC Therapeutics (ADCT), and Jazz Pharmaceuticals (JAZZ). These companies are all part of the "pharmaceutical preparations" industry.
Corcept Therapeutics (NASDAQ:CORT) and Harmony Biosciences (NASDAQ:HRMY) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, profitability, dividends, institutional ownership, earnings, analyst recommendations, community ranking, valuation and risk.
93.6% of Corcept Therapeutics shares are owned by institutional investors. Comparatively, 86.2% of Harmony Biosciences shares are owned by institutional investors. 20.5% of Corcept Therapeutics shares are owned by company insiders. Comparatively, 30.8% of Harmony Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
In the previous week, Corcept Therapeutics had 14 more articles in the media than Harmony Biosciences. MarketBeat recorded 16 mentions for Corcept Therapeutics and 2 mentions for Harmony Biosciences. Harmony Biosciences' average media sentiment score of 1.12 beat Corcept Therapeutics' score of 0.71 indicating that Harmony Biosciences is being referred to more favorably in the news media.
Corcept Therapeutics has a net margin of 22.38% compared to Harmony Biosciences' net margin of 22.30%. Harmony Biosciences' return on equity of 28.26% beat Corcept Therapeutics' return on equity.
Harmony Biosciences has higher revenue and earnings than Corcept Therapeutics. Harmony Biosciences is trading at a lower price-to-earnings ratio than Corcept Therapeutics, indicating that it is currently the more affordable of the two stocks.
Corcept Therapeutics received 483 more outperform votes than Harmony Biosciences when rated by MarketBeat users. Likewise, 70.62% of users gave Corcept Therapeutics an outperform vote while only 60.29% of users gave Harmony Biosciences an outperform vote.
Corcept Therapeutics has a beta of 0.5, meaning that its share price is 50% less volatile than the S&P 500. Comparatively, Harmony Biosciences has a beta of 0.75, meaning that its share price is 25% less volatile than the S&P 500.
Corcept Therapeutics presently has a consensus price target of $40.10, suggesting a potential upside of 42.76%. Harmony Biosciences has a consensus price target of $40.63, suggesting a potential upside of 39.94%. Given Corcept Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Corcept Therapeutics is more favorable than Harmony Biosciences.
Summary
Corcept Therapeutics beats Harmony Biosciences on 10 of the 18 factors compared between the two stocks.
Get Corcept Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CORT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CORT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Corcept Therapeutics Competitors List
Related Companies and Tools
